Contents by Year, Volume and Issue

Table of Contents

General Information

Instructions for Authors

Message to Editor

Editorial Board

>Journals >MediSan >Year 2012, Issue 05

Arredondo FA, Venet CG, Román GO, Ramírez DEY
Molecular basis of mitochondrial diseases
MediSan 2012; 16 (05)

Language: Español
References: 36
PDF: 913.75 Kb.

Full text


Mitochondria are subcellular organelles whose primary role is to produce energy, which contain their own genetic system that encodes a small number of proteins that are part of the oxidative phosphorylation system. In recent years mutations in mitochondrial genetic material have been discovered, causing mitochondrial diseases. In order to increase and update the knowledge of the subject a literature survey was performed, where the relationship of mitochondria with conditions such as Alzheimer's, Parkinson's and diabetes mellitus, to name a few, is also stated.

Key words: mitochondria, mitochondrial disease, neurodegenerative disease, aging.


  1. Campos Y. Panorámica de actualidad sobre las enfermedades mitocondriales. Madrid: Centro de Investigación Hospital 12 de Octubre; 2007.

  2. Ruiz L. La mitocondria: mucho más que una fábrica de energía [citado: 16 May 2011]. Disponible en: http://www.ecogenesis.com.ar/index.php?sec=articulo.php&Codigo=47

  3. Morrison J. Genetics of mitochondrial diseases. European J Human Genetics. 2004;12: 686_687.

  4. Hernández Rivas J. Bases moleculares de las enfermedades mitocondriales. Salamanca:Universidad Autónoma; 2008.

  5. AD therapeutic approaches tap complement, mitochondrial antioxidant [citado: 16 May 2011]. Disponible en: http://www.alzforum.org/new/detail.asp?id=2213

  6. Bell EL, Klimova T, Eisenbart J, Moraes CT, Murphy MP, et al. The Qo site of the mitochondrial complex III is required for the transduction of hypoxic signaling via reactive oxygen species production. J Cell Biol. 2007; 177: 945.

  7. Selak M, Duran R, Gottllieb E. Redox stress is not essential for the pseudo-hypoxic phenotype of succinate dehydrogenase deficient cells. Biochim Biophys Act. 2006; 1757:567-72.

  8. Finsterer J, Harbo HF, Baets J, Van Broeckhoven C, Di Donato S, Fontaine B, et al. EFNS guidelines on the molecular diagnosis of mitochondrial disorders. Eur J Neurol. 2009;16(12):1255-64.

  9. Rubio González T, Verdecia Jarque M. Las enfermedades mitocondriales: un reto para las ciencias médicas. MEDISAN 2004 [citado: 16 May 2011]; 8(1). Disponible en:http://bvs.sld.cu/revistas/san/vol8_n1_04/san08104.htm

  10. Gazdíková K, František G. Mitochondrial nephrology [citado: 16 May 2011]. Disponible en: http://www.springerlink.com/content/x15hr807555229w0/fulltext.pdf?MUD=MP

  11. Solano A, Playán A, López Pérez MJ, Montoya J. Enfermedades genéticas del ADN mitocondrial humano. Salud Pública Mex. 2001; 43:151-61.

  12. Tucker EJ, Compton AG, Thorburn DR. Recent advances in the genetics of mitochondrial encephalopathies. Curr Neurol Neurosci Rep. 2010;10(4):277-285

  13. Madamanchi R, Runge M. Mitochondrial dysfunction in atherosclerosis. Circ Res. 2007; 100(4): 460-73.

  14. Majamaa K, Winqvist S. A 3-year clinical follow-up of adult patients with 3243A>G in mitochondrial DNA. Neurology. 2006; 66(10): 1470-5.

  15. Yao J, Irwin R, Zhao L, Nilsen J, Hamilton R, Diaz Brinton R, et al. Mitochondrial bioenergetic deficit precedes Alzheimer's pathology in female mouse model of Alzheimer's disease. Proc Natl Acad Sci. 2009;106(34):14670-5.

  16. Kienhöfer J, Häussler DJ, Ruckelshausen F, Muessig E, Weber K, Pimentel D, et al. Association of mitochondrial antioxidant enzymes with mitochondrial DNA as integral nucleoid constituents. FASEB J. 2009; 23(7):2034-44.

  17. Tsutsui H, Kinugawa S, Matsushima S. Mitochondrial oxidative stress and dysfunction in myocardial remodelling Cardiovasc Res. 2009; 81(3):449-56.

  18. Fedotcheva, N, Sokolov A, Kondrashova N. Nonenzymatic formation of succinate in mitochondria under oxidative stress. Free Radic Biol Med. 2006; 41:56-64.

  19. Luoma P, Melberg A, Rinne J. Parkinsonism, premature menopause, and mitochondrial DNA polymerase gamma mutations: clinical and molecular genetic study. Lancet. 2004; 364(9437):875-82.

  20. Davidzon G, Greene P, Mancuso M, Klos KJ, Ahlskog JE, Hirano M, et al. Early-onset familial parkinsonism due to POLG mutations. Ann Neurol. 2006; 59:859-62.

  21. Hudson G, Schaefer A, Taylor RW, Tiangyou W, Gibson A, Venables G, et al. Mutation of the linker-region of POLG1 associated with PEO with parkinsonism. Arch Neurol. 2007; 64:553-7.

  22. Quintana L, Sanjurjo P. Alteraciones de la b-oxidación y del sistema de carnitina. En: Sanjurjo P, Baldellou A. Diagnóstico y tratamiento de las enfermedades metabólicas hereditarias. Madrid: Editorial Ergón; 2001.p. 275-94.

  23. Andreu L, Gonzalo Sanz R. Las enfermedades mitocondriales: una clasificación para el siglo XXI. Neurol. 2004; 19(1):15-22.

  24. Salvatore D, Michelangelo M. Mitochondrial diseases: therapeutic approaches. Biosci Rep. 2007; 27: 125-37.

  25. Saneto DO, Nicole IW, Niklas D, Bruce H. Suspected mitochondrial disorder. Inherited Metabolic Diseases. 2010; 13(1):325-33.

  26. Scharfe C, Horng-Shing Lu H, Neuenburg JK, Allen RA, Guan-Cheng L, Klopstock T, et al. PLoS Comput Biol. 2009; 5(4): e1000374.

  27. Finsterer J. Hematological manifestations of primary mitochondrial disorders. Acta Haematol. 2007; 118 (2): 88-98.

  28. Nava Reyes HJ, Zamudio Cortés P, Quiroz Cabañas Y, Martínez Ramírez I, Espinosa Pérez A, García Cruz A, et al. La disfunción mitocondrial como posible causa de la falla orgánica múltiple asociada a la sepsis severa. Rev Inst Nal Enf Resp Mex. 2009;22(1): 37-47.

  29. Gómez S, Castro O, Benavent P. MELAS: claves del diagnóstico y tratamiento en la Unidad de Cuidados Intensivos. Med Intensiva. 2008; 32(3):147-50.

  30. Vedolin L, Fischinger C. Conventional MRI and MR spectroscopy in nonclassical mitochondrial disease: report of three patients with mitochondrial DNA deletion. Child's Nervous System. 2006; 22(10):1355-9.

  31. Kam Ming Au, Shing Chi Lau. Mitochondrial DNA deletion in a girl with Fanconi's syndrome. Pediatric Nephrology. 2007; 22(1): 136-40.

  32. Martín Hernández E, García Silva MT, Quijada Fraile P, Martínez de Aragón A, Cabello A, Martín MA. Síndromes de Pearson y de Kearns-Sayre: dos enfermedades mitocondriales multisistémicas, debidas a deleciones en el ADN mitocondrial. Acta Pediatr Española. 2010; 68(9): 451-9.

  33. Martín Hernández E, García Silva MT, Vara J, Campos Y, Cabello A, Muley R, et al. Renal pathology in children with mitochondrial diseases. Pediatr Nephrol. 2005; 20(9): 1299-1305.

  34. Mitochondrial Medicine Society's Committee on Diagnosis, Haas RH, Parikh S, Falk MJ, Saneto RP, Wolf NI, et al. The in-depth evaluation of suspected mitochondrial disease. Mol Genet Metab. 2008; 94(1):16-37.

  35. Debray F, Lambert M, Chevalier I, Robitaille Y, Decarie JC, Shoubridge EA, et al. Long-term outcome and clinical spectrum of 73 pediatric patients with mitochondrial diseases. Pediatrics. 2007; 119 (4):722-33.

  36. Di Mauro S, Hirano M. Pathogenesis and treatment of mitochondrial disorders. Adv Exp Med Biol. 2009; 652:139-170.

>Journals >MediSan >Year 2012, Issue 05

· Journal Index 
· Links 

Copyright 2019